新闻中心
滑动
2025-12-17
17/ 12
大睿生物全球首款双靶点PCSK9-LPA siRNA进入临床开发，开启心血管风险治疗新阶段
2025-12-15
15/ 12
大睿生物INHBE siRNA项目推进至I期临床开发阶段
RN3161首个给药队列顺利完成
2025-11-10
10/ 11
大睿生物在2025年美国心脏协会年会上公布RN0361的I期临床数据
2025-09-15
15/ 09
大睿生物宣布RN3161澳洲临床试验申请获受理 差异化靶向INHBE siRNA进入临床，开启肥胖治疗新格局
2025-04-21
21/ 04
大睿生物宣布RN1871——靶向血管紧张素原（AGT）的siRNA药物获NMPA临床试验默示许可
2025-03-17
17/ 03
大睿生物宣布RN0361获FDA批准启动2期临床试验：针对APOC3靶点，用于治疗高甘油三酯血症的创新性siRNA疗法
Jinyu Huang, Ph.D.
Chief Executive Officer, Founder
Stella Shi is founder, Chief Executive Officer and chairs the board of Rona Therapeutics since company inception in 2021 bringing ~15 years of biopharmaceutical industry and venture capital experience. Prior to founding Rona Therapeutics, Stella was managing director in Lilly Asia Ventures (LAV) from 2015 with proven track records with various venture creation ...